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Summary
Emerging data indicate that particular major histocompatibility complex
(MHC)-bound antigenic peptides can be recognized by identical or near-
identical ab T cell receptors (TCRs) in different individuals. To establish
the functional relevance of this phenomenon, we artificially paired a and
b chains from closely related TCRs specific for the human leucocyte
antigen (HLA)-B*35:01-restricted HIV-1 negative regulatory factor (Nef)-
derived epitope VY8 (VPLRPMTY, residues 74–81). Several hybrid TCRs
generated in this manner failed to express at the cell surface, despite near
homology with naturally isolated ab chain combinations. Moreover, a
substantial proportion of those ab TCRs that did express lost specificity
for the index VY8 peptide sequence. One such hybrid ab pair gained
neo-variant specificity in the context of the VY8 backbone. Collectively,
these data show that clonotypically similar TCRs can display profound
differences in surface expression, antigen specificity and cross-reactivity
with potential relevance for the control of mutable viruses.
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Introduction
Engineered T cell receptor (TCR) gene transfer is a prom-
ising approach to the treatment of several conditions [1],
achieving notable clinical success in patients with meta-
static malignancies [2,3]. Nonetheless, outcomes vary and
there is a pressing need for improvement. Various strat-
egies have been employed to attain greater potency,
including: (i) enhancement of TCR surface expression via
human/murine constant region exchange [4] or insertion
of an additional disulphide bond in the extracellular con-
stant domain [5,6]; (ii) TCR affinity maturation via selec-
tion from randomly mutagenized receptor libraries [7]
expressed in yeast [8], phage [9–11] or other systems
[12,13]; (iii) computational design [14–16]; and (iv) tar-
geted mutagenesis within the third complementarity
determining region (CDR3), which is generally responsi-
ble for peptide antigen recognition [17–19]. All these
efforts are linked by common aims, namely engineering
TCRs towards enhanced antigen sensitivity and/or variant
epitope recognition [10].
An alternative approach to TCR engineering relies on
the generation of new specificities from naturally occur-
ring TCR sequences, exemplified by the construction of
hybrid ab TCR pairs specific for HIV-1 variants [20,21].
This strategy is enabled by a huge TCR clonotype bank,
estimated to exceed 2 3 107 unique receptors in any
given individual [22–24]. Moreover, it is established that
mixed dimers can form between endogenous and intro-
duced TCRs in primary human T cells, generating
unknown neo-reactivities [6]. Although recent studies
have implicated the variable domains and CDR3 loops as
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primary determinants of ab TCR pairing [25–27], how-
ever, our current understanding is not sufficient to pre-
dict the impact of hybridization on antigen specificity
and cross-reactivity.
Despite the immense recombinatorial potential within
the TCR repertoire, identical or closely related receptors
specific for any given epitope are observed frequently in
multiple individuals sharing a major histocompatibility
complex (MHC) restriction molecule [24,28]. These public
or near-public TCRs provide template libraries for a and b
chains with defined specificities. Hybrid combinations
derived from such libraries may therefore allow the genera-
tion of TCRs with therapeutically desirable properties, such
as improved antigen sensitivity and cross-reactivity against
naturally occurring epitope variants in vivo [10].
In the present study, we characterized TCR clonotypes
specific for the immunodominant human leucocyte antigen
(HLA)-B*35:01-restricted HIV-1 negative regulatory factor
(Nef)-derived epitope VY8 (VPLRPMTY, residues 74–81).
Although closely related TCR pairs were identified across
multiple individuals, small differences in the primary
amino acid sequence were found to exert dramatic pheno-
typic effects in terms of surface expression, antigen specific-
ity and cross-reactivity. Hybridization was also shown to
confer neo-specificities for variant antigens, an observation
with therapeutic implications for highly mutable viruses.
Materials and methods
Cell culture
The TCR-deficient mouse T cell hybridoma cell line TG40
(kindly provided by Takashi Saito, RIKEN Institute, Yoko-
hama, Japan) was maintained in RPMI-1640 containing
10% heat-inactivated fetal calf serum (FCS) (Life Technol-
ogies, Carlsbad, CA, USA). Primary CD81 T cells were
maintained in RPMI-1640 supplemented with 100 U/ml
penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine
and 10% heat-inactivated FCS (all Life Technologies),
together with 2.5% Cellkines (Helvetica Healthcare,
Geneva, Switzerland), 200 IU/ml IL-2 (PeproTech, Rocky
Hill, NJ, USA) and 25 ng/ml IL-15 (PeproTech). This study
was approved by the relevant Institutional Review Boards.
Flow cytometry
Tetrameric complexes of VY8/HLA-B*35:01 (VY8/B35)
conjugated to phycoerythrin (PE) or allophycocyanin
(APC) (Molecular Probes/Life Technologies) were prepared
as described previously [29,30]. Cells were labelled with the
VY8/B35 tetramer for 20 min at 4C and then stained with
monoclonal antibodies (mAbs) as indicated for 20 min at
4C. After two washes in phosphate-buffered saline (PBS)
containing 2% FCS, cells were fixed in 1% paraformalde-
hyde and acquired using a fluorescence activated cell sorter
(FACS)Canto II flow cytometer (BD Biosciences, San Jose,
CA, USA). Data were analysed with FlowJo software (Trees-
tar Inc., Ashland, OR, USA). The following mAbs were
used: (i) anti-human CD3-fluorescein isothiocyanate
(FITC) and anti-human CD8-APC (DakoCytomation,
Glostrup, Denmark); (ii) anti-human CD8-peridinin chlo-
rophyll protein (PerCP) (BD Biosciences); and (iii) anti-rat
CD2-PE and anti-mouse CD3e-PE (Biolegend, San Diego,
CA, USA). Dead cells were excluded from the analysis using
7-aminoactinomycin D (7-AAD) (Biolegend).
Analysis of TCR-encoding genes
TCR transcripts were amplified using a SMART PCR
cDNA Synthesis Kit (Clontech/Takara Bio Inc., Shiga,
Japan) and analysed via the ImMunoGeneTics database
(http://www.imgt.org/), as described previously [29,31].
TCR reconstruction and analysis
Full-length TCR-a and -b constructs were cloned into the
retroviral vector pMX incorporating gfp as a marker (kindly
provided by Toshio Kitamura, University of Tokyo, Japan)
and transduced into TCR-deficient TG40 and TG40/CD8
cells, as described previously [29,30,32,33]. Transductants
were identified by staining with anti-mouse CD3e-PE, and
brightly labelled cells were cloned by limiting dilution.
Assays of T cell sensitivity were performed as described pre-
viously [30]. Briefly, C1R-B*35:01 cells (104 per well) and
TCR-transduced TG40/CD8 cells (2 3 104 per well) were
incubated with peptides as indicated for 24 h at 37C.
Supernatant was then analysed for interleukin (IL)-2 con-
tent by measuring the proliferative activity of the indicator
cell line CTLL-2. Cross-reactivity was assessed against a
library of variant 11mer peptides (RPQVPLRPMTY) con-
taining the VY8 index sequence (VPLRPMTY). In the VY8
index sequence, each position was substituted with every
amino acid except cysteine to generate a total of 144 variant
peptides, as described previously [34]. Synthesized peptides
were analysed for purity by mass spectrometry and high-
performance liquid chromatography (HPLC).
TCR expression in primary CD81 T cells
Full-length TCR-a and -b constructs were cloned into the
lentiviral vector pELN (kindly provided by James L. Riley,
University of Pennsylvania, Philadelphia, USA), incorporat-
ing a pair of 2A self-cleaving peptides separating the TCR
chains and rat CD2 (rCD2) as a marker for delivery into pri-
mary CD81 T cells [10]. Briefly, CD81 T cells were isolated
from HLA-B*351 healthy donor peripheral blood mononu-
clear cells (PBMCs) and stimulated with anti-CD3/anti-
CD28 beads (Invitrogen, Carlsbad, CA, USA) for 24 h before
transduction. Transductants were enriched using magnetic
beads to yield rCD21 populations with >90% purity. Assays
of T cell sensitivity were performed as described previously
[35]. Briefly, TCR-transduced CD81 T cells (3 3 104 per
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well) were mixed with peptide-pulsed C1R-B*35:01 cells
(63 104 per well) and incubated overnight at 37C. Superna-
tant was then analysed for macrophage inflammatory protein
(MIP)-1b content by enzyme-linked immunosorbent assay
(ELISA), according to the manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA). Background values in the
absence of peptide were subtracted.
Octamer combinatorial peptide library scan
An octamer combinatorial peptide library (CPL) compris-
ing 2.4 3 1010 different peptides (PepScan, Lelystad, the
Netherlands) was divided into 160 submixtures in posi-
tional scanning format, as described previously [36–38].
Target C1R-B*35:01 cells (6 3 104 per well) were pre-
loaded with CPL submixtures (100 mg/ml) and incubated
with effector T cells (3 3 104 per well) overnight at 37C.
Supernatant was then analysed for MIP-1b content by
ELISA, as described previously [35,37–39]. The relative T
cell response is shown as fold change MIP-1b production
with respect to the lowest response at each position. A
fold response >1.5 was considered positive.
Results
TCR analysis of VY8-specific CD81 T cells
Molecular analysis of CD81 T cell clones specific for the
HIV-1 Nef-derived epitope VY8 (VPLRPMTY, residues
74–81) presented by HLA-B*35:01 [3,38,40], which is typ-
ically immunodominant in the acute/early phase of HIV-1
infection [40,41], showed that the TCR-ab variable seg-
ments were dominated by AV1 and BV11 in three different
HIV-1-infected subjects (Pt-01, Pt-19 and Pt-33) (Table
1). Similar bias was observed in VY8-specific CD81 T cell
lines derived from two additional HLA-B*35:011 HIV-1-
infected subjects (Supporting information, Fig. S1). Four
TCR-a chains exhibited highly similar CDR3a sequences,
which varied at a single amino acid position incorporating
Arg, Thr or Ser (designated A2-R, A1-R, A1-T and A1-S,
respectively) (Table 1). Two of these TCR-a chains shared
an identical CDR3a sequence combined with the related
variable segments AV1-1 or AV1-2 (designated A1-R and
A2-R) (Table 1). Three TCR-b chains with a common
BV11 variable segment (designated B11, B11-J1 and B11-
J2) displayed a conserved amino acid sequence across the
CDR3b loop (xDI/LVxxE), whereas one TCR-b chain
expressed a BV4-2 variable segment (designated B4) in
conjunction with a long CDR3b sequence rich in alanine
and aspartic acid residues (Table 1).
Functional reconstruction of naturally isolated TCR
pairs
The TCR-deficient T cell line TG40 has been used previ-
ously to examine TCR–peptide MHC (pMHC) interac-
tions [29,30,34] and characterize murine and/or human
TCR-ab pairs [29,31–33,42]. To test integrity in this sys-
tem, TG40 cells were transduced with retroviral vectors
expressing three TCR pairs (TCR-139, H127 and S1
incorporating A1-T/B11-J1, A1-J31/B11 and A2-R/B4,
respectively) isolated from CD81 T cell clones specific for
VY8 (Table 1). All three TCRs were expressed on the cell
surface. In each case, transduced T cells bound the VY8/
B35 tetramer and exhibited VY8-specific IL-2 production
(Fig. 1a), confirming specificity and functionality.
The cross-reactivity profiles of these naturally isolated
TCR pairs were examined using a set of peptides containing
substitutions with every amino acid except cysteine at each
of the eight positions along the peptide backbone (a total of
144 variant peptides) [34]. Graphical representations were
used to display the unique preferential residue recognition
signature of each TCR-a and -b pair (Fig. 1b). All TCR
pairs showed a similar cross-reactivity profile, recognizing
Table 1. T cell receptor (TCR)-ab chains used in this study
Designation V gene J gene CDR3 sequence T cell Subject
TRA A2-R AV1-2*01 AJ26*01 CAV RDNYGQN FVF Clone-S1 Pt-33
A1-R AV1-1*01 AJ26*01 CAV RDNYGQN FVF Line-100 Pt-100
A1-T AV1-1*01 AJ26*01 CAV TDNYGQN FVF Clone-139 Pt-19
A1-S AV1-1*01 AJ26*01 CAV SDNYGQN FVF Line-100 Pt-100
A1-J31 AV1-1*01 AJ31*01 CAV TSGDAR LMF Clone-H127 Pt-01
AV1-2*01 AJ31*01 CAV EGDNAR LMF Clone-H218 Pt-01
AV1-1*01 AJ31*01 CAV RDGGNNAR LMF Clone-136 Pt-19
TRB B11 BV11-1*01 BJ2-7*01 CASS SDIVSYE QYF Clone-H127 Pt-01
B11-J1 BV11-2*01 BJ1-1*01 CASS LDLVSTE AFF Clone-139 Pt-19
B11-J2 BV11-2*01 BJ2-1*01 CASS PDLVDNE QFF Line-100 Pt-100
B4 BV4-2*01 BJ2-3*01 CASS QAADAAITDADT QYF Clone-S1 Pt-33
BV4-2*01 BJ2-1*01 CASS PEVAANNE QFF Clone-H218 Pt-01
BV7-2*03 BJ2-1*01 CASS PTPQGDYE QFF Clone-136 Pt-19
Underlining in CDR3a and CDR3b represents amino acid differences and conserved amino acids, respectively. A1-T/B11-J1, A1-J31/B11 and
A2-R/B4 are naturally isolated TCR pairs from clones 139 (Pt-19), H127 (Pt-01) and S1 (Pt-33).
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multiple amino acids at P1, but only limited numbers of
substitutions at P2, P4 and P6 (Fig. 1b). However, TCR-139
and S1 recognized a wider range of hydrophobic residues
such as Leu, Val, Met, Phe and Ala at P3, whereas H127 rec-
ognized only Leu and Met at this position (Fig. 1b). These
results suggest that individual TCR-a and -b chains can
confer unique antigen recognition profiles.
Cell surface expression and epitope specificity of
hybrid TCR pairs
To test the antigen specificity of hybrid TCR pairs, TG40
cells were transduced with retroviral vectors expressing 16
different combinations of VY8-specific TCR-a and -b
chains (Table 1). Cell surface TCR/CD3 expression was
detected for 14 of 16 hybrid pairs, only seven of which
Fig. 1. Reconstruction of naturally isolated T cell receptor (TCR) pairs. (a) TCR-deficient TG40 cells expressing the naturally isolated ab TCR
pairs A1-T/B11-J1 (TCR-139), A1-J31/B11 (H127) or A2-R/B4 (S1) were stained with anti-CD3 monoclonal antibody (mAb) (top row) or VY8/
B35 tetramer (middle row) and analysed by flow cytometry. Mock-transduced TG40 cells were used as negative controls. Tetramer staining is
depicted as mean fluorescence intensity after gating on 7-aminoactinomycin D (7-AAD)– green fluorescent protein (GFP)1CD311 cells. To assess
T cell sensitivity (bottom row), TCR genes were delivered into TG40 cells expressing human CD8a, as described previously [34]. CD31 cells
were then enriched using magnetic beads and analysed for interleukin (IL)-2 secretion in response to various concentrations of VY8 peptide. The
amount of IL-2 obtained with mock-transduced TG40 cells was consistently <5.0 U/ml and the amount of IL-2 secreted by TCR-transduced
TG40 cells was expressed as % maximal, normalized with respect to the anti-CD3 mAb-mediated activation. Data are representative of duplicate
assays. (b) TCR cross-reactivity was evaluated against a library of peptides in which each position was substituted with every amino acid except
cysteine to generate a total of 144 individual variants (5 mM per peptide). Antigen sensitivity was calculated as the percent of maximum response
compared to anti-CD3 mAb-stimulated cells. Graphical representations showing relative preferences for amino acid residues at each position were
generated using WebLogo 3 (http://weblogo.threeplusone.com/) [38]. Colours represent physicochemical properties: green, polar (G, S, T, Y and
C); purple, neutral (Q and N); blue, basic (K, R and H); red, acidic (D and E); black, hydrophobic (A, V, L, I, P, W, F and M). The index
residue at each position is outlined in yellow. Residue size is proportional to T cell recognition preference.
Properties of hybrid ab TCRs
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showed VY8/B35 tetramer binding and VY8-specific IL-2
production (Fig. 2). Three TCR-a chains with a single
amino acid difference in the CDR3a loop (A1-T, A1-S
and A1-R) were expressed at the cell surface in complex
with all TCR-b chains except B4 (Fig. 2a). None of the
TCR pairs with A1-R showed VY8 specificity. Of note,
tetramer binding intensity and antigen sensitivity did not
correlate for some hybrid TCRs, such as A1-T/B11 and
A1-S/B11 (Fig. 2d).
Next, we examined the impact of AV1-1 and AV1-2 on
TCR expression and antigen specificity. The backbone
framework of these variable segments differs at 17 of 128
amino acid positions (ImMunoGeneTics database; http://
www.imgt.org/). The A1-R and A2-R TCR-a chains also
exhibit amino acid differences in the CDR1a (TSGFYG
and TSGFNG) and CDR2a (NALDGL and NVLDGL)
loops. Although A2-R/B4 was expressed at the cell surface
and displayed VY8 specificity comparable to other natu-
rally isolated TCR pairs, substitution of the TCR-a chain
with A1-R substantially decreased TCR/CD3 surface
expression and abrogated VY8 specificity (Fig. 2a). In
addition, other TCR-a chains (A1-T and A1-S) failed to
express in combination with B4 (Fig. 2a). These results
suggest that the germline-derived sequence contributes to
functional TCR-ab heterodimer formation and T cell
specificity.
Fig. 2. Reconstruction of hybrid T cell receptors (TCRs). (a–d) The indicated combinations of TCR-a (A1-T, A1-S, A1-R and A2-R) and -b (B4,
B11-J1, B11-J2 and B11) chains were analysed for cell surface expression of TCR/CD3, VY8/B35 tetramer binding and VY8 reactivity, as
described in Fig. 1a.
C. Motozono et al.
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Cross-reactivity profiles of hybrid TCR pairs
Next, we tested the cross-reactivity profiles of hybrid TCR
pairs against variant peptides. Single amino acid differences in
the CDR3a loop and TCR-ab pairing substantially affected
fine specificity (Fig. 3). The A1-T chain showed a similar
cross-reactivity profile combined with B11-J1 (a naturally iso-
lated TCR pairing), B11-J2 or B11 (Fig. 3a–c). In contrast, the
CDR3a Thr to Ser mutation (A1-T to A1-S) dramatically
decreased cross-reactivity at P1, P3 and P7 when combined
with B11-J1 (Fig. 3a), an effect that was compensated by
switching the TCR-b chain to B11-J2 or B11 (Fig. 3b,c).
Although positively charged residues (Lys and Arg) at P4 were
required for recognition by various VY8-specific CD81 T cell
clones [38], as well as most of the hybrid pairs bearing A1-T
but not A1-S (Figs. 1 and 3), TCRs with the A1-R chain in
combination with any of the three TCR-b chains favoured
hydrophobic residues (Ile and Leu) at this position (Fig. 3).
These data explain why TCRs incorporating A1-R lose VY8
specificity (Fig. 2), and suggest that clonotypically similar
hybrid receptors can acquire neo-variant specificities.
Hybrid TCR expression, specificity and
cross-reactivity in primary CD81 T cells
To confirm the antigen specificity of T cells expressing
hybrid TCR pairs, B11-J1 receptors paired with A1-T,
A1-S or A1-R were introduced into primary CD81 T cells
and enriched on the basis of rCD2 expression to >90%
purity (Fig. 4a). CD81 T cells expressing the naturally
isolated TCR pair A1-T/B11-J1 stained efficiently with the
VY8/B35 tetramer, confirming the integrity of TCR recon-
struction (Fig. 4b). In contrast, CD81 T cells expressing
A1-S stained moderately with the VY8/B35 tetramer and
those expressing A1-R stained poorly (Fig. 4b), confirm-
ing the data obtained using TG40 cells (Fig. 2). Moreover,
CD81 T cells expressing A1-T and A1-S, but not A1-R,
recognized target cells pulsed with the index VY8 peptide
(Fig. 4c). Conversely, CD81 T cells expressing A1-R dis-
played a unique reactivity against the variant peptide
with Leu at P4, which was not recognized by cells
expressing A1-T or A1-S (Fig. 4c). Again, these patterns
are consistent with the data generated using TG40 cells
(Figs 2b, 3a).
To clarify these changes in antigen specificity towards
not only substitutions within the VY8 peptide backbone
but also towards all possible amino acid combinations of
the octamer peptide, we employed a library containing
2.4 3 1010 different octamer peptides, which enabled
qualitative mapping of preferred T cell recognition resi-
dues at each position along the peptide backbone [38]
(Fig. 5). Primary CD81 T cells expressing A1-T recog-
nized the index amino acid at each position, consistent
with previous observations [38]. Conversely, CD81
T cells expressing A1-S or A1-R showed different patterns
of cross-reactivity with reduced recognition of the index
Arg residue at P4 as well as other amino acids, such as
Fig. 3. Cross-reactivity of hybrid T cell receptors
(TCRs). (a–c) The indicated combinations of
TCR-a (A1-T, A1-S and A1-R) and -b (B11-J1,
B11-J2 and B11) chains were analysed for cross-
reactivity, as described in Fig. 1b.
Properties of hybrid ab TCRs
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Pro at P5 and Met at P6 (Fig. 5). These data further sup-
port the notion that closely related hybrid TCRs can dis-
play substantial differences in fine specificity.
Discussion
In this study, we artificially paired a and b chains from
clonotypically similar TCRs specific for the HLA-B*35:01-
restricted HIV-1 Nef-derived epitope VY8 to examine the
impact of recombinatorial sequence diversity on receptor
expression, antigen specificity and cross-reactivity. The
key findings were as follows: (i) some hybrid TCRs failed
to express at the T cell surface despite close homology
with naturally isolated ab chain combinations; (ii)
approximately 50% of those ab TCRs that expressed lost
specificity for the index VY8 peptide sequence; and (iii)
allelic differences between AV1-1 and AV1-2, and an
amino acid change in the CDR3a loop, not only altered
surface TCR/CD3 levels, index peptide recognition and
cross-reactivity profiles, but also generated neo-
specificities for variant antigens. These data demonstrate
that even small differences between paired a and b chain
sequences generated naturally in response to a given anti-
gen can dramatically influence the physical and functional
properties of the resultant TCR.
Public or near-public TCRs have been identified in
antigen-specific CD81 T cell responses to variable patho-
gens such as HIV and simian immunodeficiency virus
(SIV) [24,28], and the highly focused nature of these
biased repertoires can facilitate immune escape under cer-
tain conditions [43,44]. Accordingly, we hypothesized
that hybrid TCRs with intact surface expression and HIV-
1-derived epitope specificity could be constructed by
shuffling such closely related a and b chains. Of 16 ab
combinations, however, only seven pairs generated TCRs
that retained cell surface expression and index epitope
specificity. In addition, some hybrid TCRs that lost reac-
tivity against the index epitope displayed neo-specificities
for variant peptides. These results demonstrate that clo-
notypically similar TCRs are partner chain-dependent and
cannot be considered functionally equivalent. Structural
approaches are warranted to determine how allelic differ-
ences and an amino acid change in the CDR3a loop alter
Fig. 4. Reconstruction of hybrid T cell receptors
(TCRs) in primary CD81 T cells. (a–c) Primary
CD81 T cells transduced with the indicated TCR
pairs were examined for rCD2 expression (a),
VY8/B35 tetramer staining after gating on 7-
aminoactinomycin D (7-AAD)–CD81 cells (b)
and macrophage inflammatory protein (MIP)-1b
production in response to peptide stimulation
(c). In (a) and (b), data are representative of
duplicate assays. In (b), the percentage and mean
fluorescence intensity of live tetramer1 CD81 T
cells are indicated in each histogram. In (c),
standard deviation from the mean of two
replicates is shown.
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Fig. 5. Cross-reactivity of hybrid T cell receptors (TCRs) in primary CD81 T cells. Primary CD81 T cells expressing hybrid TCRs were tested for
preferred recognition residues at each position along the peptide backbone using an octamer combinatorial peptide library incorporating a total
of 2.4 3 1010 different octamer peptides. In each of 160 peptide submixtures, one position was fixed with a defined amino acid residue and all
other positions were degenerate, including any amino acid except cysteine. Macrophage inflammatory protein (MIP)-1b release was quantified by
enzyme-linked immunosorbent assay (ELISA). Responses are shown as fold change MIP-1b production relative to the lowest response at each
position defined as 1.0. Background responses were 70 6 8.9 pg/ml and the lowest response for CD81 T cells expressing A1-T, A1-S and A1-R at
each position were 183 6 26, 93 6 44 and 122 6 19 pg/ml, respectively. Fold changes >1.5 were considered positive. A representative set of
duplicate assays is shown. Black bars depict residues corresponding to the VY8 index sequence.
Properties of hybrid ab TCRs
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TCR pairing and specific antigen contacts at the molecu-
lar interface.
In broad terms, the CDR1 and CDR2 loops predomi-
nantly engage the presenting MHC molecule, whereas the
CDR3 loops are typically orientated to interact primarily
with the bound peptide epitope [45,46]. The CDR3 loop
is highly variable as a result of somatic V-(D)-J rearrange-
ment and junctional diversification [47]. In our analysis
of naturally arising VY8-specific TCRs, we identified
closely-related AV1-1/AJ26 a chains that differed at a sin-
gle position with Thr, Ser or Arg in the CDR3a loop.
Shuffling studies revealed that both A1-T and A1-S
retained VY8 specificity and showed similar TCR cross-
reactivity profiles in combination with different BV11 b
chains (B11-J1, B11-J2 and B11) (Fig. 3). Similar findings
have been reported previously, where specific a chains
were able to pair productively with multiple b chains in
the context of a single TCR specificity [25,26,32].
It is notable that the B4 b chain exhibited a long
CDR3b loop and limited capacity to pair with alternate
a chains (Fig. 2). This observation is consistent with a
previous report showing the TCR-ab pairing being inhib-
ited by a long CDR3 loop [27]. Conversely, A2-R only
paired with the B4 b chain. Furthermore, A2-R failed to
recognize VY8 or any single-substituted peptide variants
thereof (n = 144) in partnership with B11-J1, B11-J2 or
B11 (data not shown), whereas A1-R paired with these b
chains recognized variant peptides substituted at P4.
Germline-encoded differences in the a chain may there-
fore play a crucial role in TCR pairing, antigen specificity
and cross-reactivity. In support of this notion, a recent
structural study showed that allelic variation (Gln and
His) in public b chains (BV9-1 and BV9-2) specific for
the HLA-B*35:01-restricted Epstein–Barr virus (EBV)
EBNA-1-derived epitope HY11 (HPVGEADYFEY, residues
407-417) affected charge complementarity at the TCR/
pMHC interface [48].
Some limitations of our study merit mention. First,
studies of TCR pairing and antigen specificity feature
numerous challenges and limitations. For example,
although a variety of human TCR-ab chains are physi-
cally and functionally reconstructed on the surface of
murine-derived cells [29–33,42] as well as human T cells
[25,27,33,49], non-physiological constraints on the hybrid
TCR/CD3 complex may complicate data interpretation
[50]. Indeed, some human TCR-ab pairs such as A1-T/
B4 and A1-S/B4 failed to express as TCR/CD3 on the
TG40 cell surface in this study (Fig. 2a). However, the B4
b chain can be expressed as TCR/CD3 on the TG40 cell
surface when combined with A2-R and A1-R (Fig. 1a), as
well as other AV1-21 TCR-a chains (data not shown),
confirming the functionality of the TCR-a and -b chains
used in the study. Further studies are needed to elucidate
comprehensively the molecular basis of the TCR-ab het-
erodimer assembly in the context of the TCR/CD3 com-
plex on the cell surface [50]. Second, prediction of
specific recognition patterns from primary TCR sequence
data is still a challenging task. Here, we examined a set of
very similar TCR-ab pairs for antigen specificity and
cross-reactivity by using HLA tetramers, T cell stimula-
tion assay, and combinatorial libraries. Although the
results do not suggest common and shared pathway(s)
for determination of TCR specificity and cross-reactivity
our data highlight, rather, that clonotypically similar
TCRs can display profound differences in surface expres-
sion, antigen specificity and cross-reactivity. These find-
ings suggest that even minor recombinatorial variability
can expand the composite functional capabilities of any
given antigen-specific TCR repertoire, potentially enabling
enhanced immune control in the case of highly mutable
viruses while avoiding detrimental cross-reactivity or
autoreactivity. Further investigations of a variety of TCRs
specific for other pathogens and tumours are warranted.
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Fig. S1. T cell receptor (TCR) usage in VY8-specific
CD81 T cell lines. (a, b) Usage of human T cell receptor
alpha variable region (TRAV) (a) and human T cell
receptor beta variable (TRBV) (b) segments in VY8-
specific CD81 T lines generated from two human leuco-
cyte antigen (HLA)-B*351 subjects infected with HIV-1
(Pt-100 and Pt-168). Peripheral blood mononuclear cells
(PBMCs) were stimulated with index peptide for 2 days
and VY8/B35 tetramer1 CD81 T cell populations were
sorted by flow cytometry.
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